sur Evotec AG (NASDAQ:EVTCY)
Evotec Announces Outcomes of 2026 Annual General Meeting
On June 11, 2026, Evotec SE disclosed the results of its Annual General Meeting, held in Hamburg. All proposed agenda items received approval from shareholders. Notably, Dieter Weinand and Dr. Wolfgang Hofmann were newly elected to the Supervisory Board, with Weinand subsequently appointed as Chairman, taking over from Prof. Dr. Iris Löw-Friedrich. Furthermore, Dr. Duncan McHale and Wesley Wheeler were re-elected to the Board.
The meeting saw participation representing 43.10% of Evotec's registered share capital. The company is set to release detailed voting results and additional information on their website shortly.
Evotec, listed on NASDAQ and Frankfurt Prime Standard, operates in the life sciences sector with a focus on drug discovery and development. The company's initiatives blend pioneering science with AI and cutting-edge technologies, aiming to enhance efficiency in therapeutics.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Evotec AG